|
gptkbp:instanceOf
|
gptkb:antibiotic
gptkb:cephalosporin
|
|
gptkbp:approvedBy
|
1979
|
|
gptkbp:ATCCode
|
J01DC04
|
|
gptkbp:bioavailability
|
95%
|
|
gptkbp:brand
|
gptkb:Ceclor
gptkb:Distaclor
gptkb:Keflor
|
|
gptkbp:CASNumber
|
53994-73-3
|
|
gptkbp:chemicalFormula
|
C15H14ClN3O4S
beta-lactam ring
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
|
|
gptkbp:discoveredIn
|
1970s
|
|
gptkbp:drugClass
|
gptkb:second-generation_cephalosporin
|
|
gptkbp:eliminationHalfLife
|
0.6–0.9 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
gptkb:tablet
capsule
oral suspension
|
|
gptkbp:indication
|
gptkb:otitis_media
tonsillitis
urinary tract infections
respiratory tract infections
pharyngitis
skin and soft tissue infections
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
367.81 g/mol
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
B1 (Australia)
B (US FDA)
|
|
gptkbp:prescribes
|
adults
children
elderly
|
|
gptkbp:proteinBinding
|
23.5%
|
|
gptkbp:riskFactor
|
cross-reactivity with penicillin allergy
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
abdominal pain
rash
allergic reactions
serum sickness-like reaction
|
|
gptkbp:spectrumOfActivity
|
Gram-positive bacteria
some Gram-negative bacteria
|
|
gptkbp:usedFor
|
bacterial infections
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
not included
|
|
gptkbp:bfsParent
|
gptkb:D01841
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cefaclor
|